Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

INTRODUCTION: We report the impact of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, on inflammation and health-related quality of life (HRQoL) in patients with difficult-to-treat Gouty Arthritis. METHODS: In this eight-week, single-blind, double-dummy, dose-ranging study, patients with acute Gouty Arthritis flares who were unresponsive or intolerant to--or had contraindications for--non-steroidal anti-inflammatory drugs and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg) (N = 143) or an intramuscular dose of triamcinolone acetonide 40 mg (N = 57). Patients assessed pain using a Likert scale, physicians assessed clinical signs of joint inflammation, and HRQoL was measured using the 36-item Short-Form Health Survey (SF-36) (acute version). RESULTS: At baseline, 98% of patients were suffering from moderate-to-extreme pain. The percentage of patients with no or mild pain was numerically greater in most canakinumab groups compared with triamcinolone acetonide from 24 to 72 hours post-dose; the difference was statistically significant for canakinumab 150 mg at these time points (P < 0.05). Treatment with canakinumab 150 mg was associated with statistically significant lower Likert scores for tenderness (odds ratio (OR), 3.2; 95% confidence interval (CI), 1.27 to 7.89; P = 0.014) and swelling (OR, 2.7; 95% CI, 1.09 to 6.50, P = 0.032) at 72 hours compared with triamcinolone acetonide. Median C-reactive protein and serum amyloid A levels were normalized by seven days post-dose in most canakinumab groups, but remained elevated in the triamcinolone acetonide group. Improvements in physical health were observed at seven days post-dose in all treatment groups; increases in scores were highest for canakinumab 150 mg. In this group, the mean SF-36 physical component summary score increased by 12.0 points from baseline to 48.3 at seven days post-dose. SF-36 scores for physical functioning and bodily pain for the canakinumab 150 mg group approached those for the US general population by seven days post-dose and reached norm values by eight weeks post-dose. CONCLUSIONS: Canakinumab 150 mg provided significantly greater and more rapid reduction in pain and signs and symptoms of inflammation compared with triamcinolone acetonide 40 mg. Improvements in HRQoL were seen in both treatment groups with a faster onset with canakinumab 150 mg compared with triamcinolone acetonide 40 mg. TRIAL REGISTRATION: clinicaltrials.gov: NCT00798369.

Footnotes, May, 2001 Vol.25, no. 5

Monthly newsletter of the State Library of Iowa

Footnotes, June/July 2001, Vol.25, no.6/7

Monthly newsletter for the State Libary of Iowa

Footnotes August/Septmeber 2001, Vol.25 no.8/9

Monthly newsleter of the State Library of Iowa

Footnotes October/November 2001, Vol.25, no.10/11

Monthly newsletter for the State Library of Iowa

Footnotes December 2001, Vol.25, no.12

Monthly newsletter of the State Library of Iowa

IDED Quick News July 25, 2003

Newsletter for Economic Development

Seguimento do enfermeiro graduado na Escola de Enfermagem da USP: sua inserção em Unidades de Terapia Intensiva

O estudo foi realizado com os objetivos de identificar as atividades desenvolvidas após a formatura pelos enfermeiros graduados na Escola de Enfermagem da SP (EEUSP) e caracterizar a inserção destes enfermeiros em Unidades de Terapia Intensiva (UTIs) no que se refere a ter sido ou não sua primeira área de atuação, à experiência anterior de trabalho em UTI, ao treinamento inicial específico e às dificuldades enfrentadas para assumir as atividades nessas Unidades. A população foi composta pelos egressos da EEUSP nos anos de 1991 a 1995. Uma listagem dos alunos formados no período, com os respectivos endereços e telefones, foi obtida junto à Seção de Graduação. Foi utilizado um questionário para a coleta de dados. Dentre os 235 questionários enviados, 117 (49,8%) retornaram com resposta. Quanto as atividades após a formatura, 90,5% informaram estar exercendo a profissão; o hospital ,foi o local de trabalho mais indicado, totalizando 76,2% das respostas. Em todos os anos do período estudado, um contingente significativo de enfermeiros foi absorvido nas UTls. Dos 117 respondentes, 55 (47,0%) informaram que trabalham ou trabalharam em UTI, sendo que para 54,5% deles, este foi o primeiro emprego. A maioria (52,8%) não tinha experiência de trabalho anterior em UTI. Apesar de 64,1% dos enfermeiros terem recebido treinamento inicial específico, foram mencionadas dificuldades para assumir as atividades na UTI, dentre as quais destacaram-se: a falta de destreza manual e de conhecimento teórico (45,4%), o manuseio de equipamentos (25,8%) e o relacionamento com as equipes de enfermagem. e multiprofissional (8,2%).

ABD e-News, July 25, 2003

Newsletter for State of Iowa Alcoholic Beverages Division

Lottery Action, August 25-September 7, 2003, Vol. 10, no. 17

Iowa Lottery Authority Retailer Information Newsletter

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m(2). Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m(2). Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. CONCLUSION Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thrombocytopenia as the main toxicity.

Parc des princes, 25-1-20, équipe [de rugby] de Grenoble [F.C.G.] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57762

Parc des princes, 25-1-20, équipe [de rugby] de Grenoble [F.C.G.] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57763

Parc des princes, 25-1-20, équipe [de rugby] du Stade [français] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57761

Parc des princes, 25-1-20, équipe [de rugby de la société] Générale : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57758